

# Tord Inghardt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4696043/publications.pdf>

Version: 2024-02-01

9  
papers

108  
citations

1307594

7  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

183  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3K $\beta$ inhibitors, useful as antiplatelet agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3936-3943.	2.2	23
2	Discovery of phosphoinositide 3-kinases (PI3K) p110 $\beta$ isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6671-6676.	2.2	18
3	Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3K $\beta$ inhibitors for the treatment of PTEN-deficient tumours. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3928-3935.	2.2	18
4	Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4274-4279.	2.2	13
5	A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 15000-15004.	13.8	10
6	Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4268-4273.	2.2	9
7	Discovery of 1,3-disubstituted-1H-pyrrole derivatives as potent Melanin-Concentrating Hormone Receptor 1 (MCH-R1) antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4859-4863.	2.2	8
8	Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1241-1245.	2.2	6
9	A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding. <i>Angewandte Chemie</i> , 2019, 131, 15142-15146.	2.0	3